Cargando…

Rapid resistance profiling of SARS-CoV-2 protease inhibitors

Mostrar otras versiones (1)

Resistance to nirmatrelvir (Paxlovid) has been shown by multiple groups and may already exist in clinical SARS-CoV-2 isolates. Here a panel of SARS-CoV-2 main protease (M(pro)) variants and a robust cell-based assay are used to compare the resistance profiles of nirmatrelvir, ensitrelvir, and FB2001...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moghadasi, Seyed Arad, Biswas, Rayhan G., Harki, Daniel A., Harris, Reuben S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002627/ https://www.ncbi.nlm.nih.gov/pubmed/36909573 http://dx.doi.org/10.1101/2023.02.25.530000

Ejemplares similares

Rapid resistance profiling of SARS-CoV-2 protease inhibitors
por: Moghadasi, Seyed Arad, et al.
Publicado: (2023)

Developing inhibitors of the SARS-CoV-2 main protease
por: Seitz, Christian, et al.
Publicado: (2022)

Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors
por: Moghadasi, Seyed Arad, et al.
Publicado: (2022)

Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors
por: Moghadasi, Seyed Arad, et al.
Publicado: (2023)

Studies on antiviral resistant SARS-CoV-2 Mpro mutants
por: Esler, Morgan A., et al.
Publicado: (2023)

Gain-of-function assay for SARS-CoV-2 M(pro) inhibition in living cells
por: Moghadasi, Seyad Arad, et al.
Publicado: (2020)

A comprehensive study of SARS-CoV-2 main protease (M(pro)) inhibitor-resistant mutants selected in a VSV-based system
por: Costacurta, Francesco, et al.
Publicado: (2023)

DNA-encoded chemical libraries yield non-covalent and non-peptidic SARS-CoV-2 main protease inhibitors
por: Jimmidi, Ravikumar, et al.
Publicado: (2023)

Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 M(pro)/3CL(pro) in Living Cells
por: Moghadasi, Seyed Arad, et al.
Publicado: (2022)

Insect protease inhibitors; promising inhibitory compounds against SARS-CoV-2 main protease
por: Hemmati, Seyed Ali, et al.
Publicado: (2022)

Rapid structure-based identification of potential SARS-CoV-2 main protease inhibitors
por: Sobhia, M Elizabeth, et al.
Publicado: (2021)

Potential SARS-CoV-2 main protease inhibitors
por: Banerjee, Riddhidev, et al.
Publicado: (2021)

Allosteric inhibitors of the main protease of SARS-CoV-2
por: Samrat, Subodh Kumar, et al.
Publicado: (2022)

SARS-CoV-2 3CL(pro) mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376
por: Heilmann, Emmanuel, et al.
Publicado: (2022)

Rapid SARS-CoV-2 Adaptation to Available Cellular Proteases
por: Chaudhry, M. Zeeshan, et al.
Publicado: (2022)

Biochemical screening for SARS-CoV-2 main protease inhibitors
por: Coelho, Camila, et al.
Publicado: (2020)

Discovery of M Protease Inhibitors Encoded by SARS-CoV-2
por: Hung, Hui-Chen, et al.
Publicado: (2020)

Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors
por: Huff, Sarah, et al.
Publicado: (2021)

Fullerene derivatives as inhibitors of the SARS-CoV-2 main protease
por: Katagishi, Daiki, et al.
Publicado: (2023)

Potent and biostable inhibitors of the main protease of SARS-CoV-2
por: Tsuji, Kohei, et al.
Publicado: (2022)

Non-conventional interactions of N3 inhibitor with the main protease of SARS-CoV and SARS-CoV-2
por: García-Gutiérrez, Ponciano, et al.
Publicado: (2021)

Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2′s main protease
por: Mahdi, Mohamed, et al.
Publicado: (2020)

Rapid prediction of possible inhibitors for SARS-CoV-2 main protease using docking and FPL simulations
por: Pham, Minh Quan, et al.
Publicado: (2020)

Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease
por: Mengist, Hylemariam Mihiretie, et al.
Publicado: (2021)

Protegrin-2, a potential inhibitor for targeting SARS-CoV-2 main protease M(pro)
por: Jan, Zainab, et al.
Publicado: (2023)

Evaluation of Xa inhibitors as potential inhibitors of the SARS-CoV-2 Mpro protease
por: Papaj, Katarzyna, et al.
Publicado: (2022)

Design, synthesis and docking study of Vortioxetine derivatives as a SARS-CoV-2 main protease inhibitor
por: Suryavanshi, Hemant, et al.
Publicado: (2022)

Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors
por: Kumar, Vathan, et al.
Publicado: (2016)

Identification of alkaloids from Justicia adhatoda as potent SARS CoV-2 main protease inhibitors: An in silico perspective
por: Ghosh, Rajesh, et al.
Publicado: (2021)

Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332
por: Zhao, Yao, et al.
Publicado: (2021)

Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases
por: Park, Ji-Young, et al.
Publicado: (2012)

In silico Exploration of Inhibitors for SARS-CoV-2's Papain-Like Protease
por: Huynh, Tien, et al.
Publicado: (2021)

Computational Prediction of Potential Inhibitors of the Main Protease of SARS-CoV-2
por: Abel, Renata, et al.
Publicado: (2020)

Computational Selectivity Assessment of Protease Inhibitors against SARS-CoV-2
por: Fischer, André, et al.
Publicado: (2021)

Validation and Invalidation of SARS-CoV-2 Papain-like Protease Inhibitors
por: Ma, Chunlong, et al.
Publicado: (2022)

A cyclic peptide inhibitor of the SARS-CoV-2 main protease
por: Kreutzer, Adam G., et al.
Publicado: (2021)

Fragment-based inhibitor design for SARS-CoV2 main protease
por: Andola, Priyanka, et al.
Publicado: (2022)

Discovery of 3CLpro inhibitor of SARS-CoV-2 main protease
por: Kuang, Yi, et al.
Publicado: (2023)

Multicomponent Synthesis of the SARS-CoV-2 Main Protease Inhibitor Nirmatrelvir
por: Preschel, H. Daniel, et al.
Publicado: (2023)

Screening, Synthesis and Biochemical Characterization of SARS-CoV-2 Protease Inhibitors
por: Bagdonas, Martynas, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kkgp0gqco1rjagid1o0ld3mj80